Vaccine therapy for prostate cancer

Vaccine therapy may provide an alternative for prostate cancer patients who se disease no longer responds to hormone therapy. Administration of dendrit ic cells pulsed with prostate-specific membrane antigen (PSMA) induces cell ular immune responses against the tumor with virtually no adverse effects. About 30% of the evaluable patients were identified as partial responders, based on the National Prostate Cancer Project (NPCP) criteria. In addition, there was a 50% decrease of serum prostate-specific antigen or resolution of previously measurable lesions on imaging. Dendritic cell vaccine therapy may have a synergistic effect, when combined with other therapies.